Compare iShares MSCI India ETF (INDA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: iShares MSCI India ETF is far larger — about 6.8× Sana Biotechnology Inc's market cap, and iShares MSCI India ETF is more actively traded (6,797,522 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Sana Biotechnology Inc for 23 Days on average.
| INDA | SANA | |
|---|---|---|
Market Cap | $5.73B | $836.71M |
Volume | 6,797,522 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $5.92 |
52-Week Low | $45.42 | $2.68 |
Typical Hold Time | 58 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $45.98, down 0.3% with bearish technical signals showing 19 sell indicators versus 5 buy signals. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and pharma sector export issues. Technical indicators show oversold conditions with RSI readings below 16, suggesting potential for near-term bounce despite the dominant bearish trend.
The outlook remains cautious as India's market composition with heavy banking sector exposure and external pressures from US tariff tensions create uncertainty. Key support at $45 provides critical technical level, while sector-specific challenges in technology and pharmaceuticals warrant careful monitoring of India's economic resilience.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
